AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
Vasomune and AnGes Announce First Patient Enrolled in Phase 2a Clinical Study Evaluating AV-001 for the Treatment of Severe COVID-19 Disease
Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. January 18, 2022 08:00 AM Eastern Standard Time TORONTO--(BUSINESS WIRE)--Vasomune…
Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic
Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the Development of AV-001 for the…
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy AV-001 was Safe and Well-Tolerated in Healthy Volunteers Vasomune plans to initiate a Phase 2a proof-of-concept study…
Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19
Vasomune is very pleased to announce that the company has received a substantial investment on behalf of the Government of Canada through the National Research Council (NRC) for Vasomune's continued…
Vasomune Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment
First subjects have been dosed in Phase 1 study of AV-001, a novel first-in-class therapeutic Should the Phase 1 results show AV-001 is safe and well-tolerated, Vasomune will initiate a…
Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19
TORONTO, Ontario - (Business Wire) – November 12, 2020 - Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has allowed its Investigational…
Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing
Vasomune Therapeutics has been working with University of Iowa Pharmaceuticals (UIP) through a strategic partnership toward the manufacture of AV-001, a biopharmaceutical therapeutic that treats acute respiratory distress syndrome (ARDS)…
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19 TORONTO, Ontario -…
Vasomune Therapeutics Announces Clinical and Scientific Advisory Board
Vasomune Therapeutics Announces Clinical and Scientific Advisory Board Esteemed Leaders in Translation, Therapeutic Development and Critical Care Medicine TORONTO, Ontario – (Business Wire) – May 11, 2020 – Vasomune Therapeutics,…